Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 360-degree synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing number of organ transplant procedures
3.2.1.2 Rising prevalence of autoimmune diseases
3.2.1.3 Surge in immunosuppressive research and development activities
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects and the availability of the alternative treatments
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Reimbursement scenario
3.6 Technological landscape
3.7 Porter's analysis
3.7.1 Supplier power
3.7.2 Buyer power
3.7.3 Threat of new entrants
3.7.4 Threat of substitutes
3.7.5 Industry rivalry
3.8 PESTEL analysis
3.9 Future market trends
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Injections
5.3 Tablets and capsules
5.4 Ointments
5.5 Granules
Chapter 6 Market Estimates and Forecast, By Application, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Dermatitis
6.3 Immunosuppression
6.4 Other applications
Chapter 7 Market Estimates and Forecast, By End-Use, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospitals
7.3 Specialty clinics
7.4 Other end-users
Chapter 8 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 Saudi Arabia
8.6.2 South Africa
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Abbott Laboratories
9.2 Astellas Pharma Inc.
9.3 Biocon Ltd.
9.4 F. Hoffmann-La Roche Ltd
9.5 Glenmark Pharmaceuticals Inc.
9.6 GSK plc
9.7 Lupin Pharmaceuticals Ltd.
9.8 Novartis AG
9.9 Pfizer Inc.
9.10 Takeda Pharmaceutical Company Limited
9.11 Viatris Inc.
